Crenessity (crinecerfont) — Highmark
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD)
Initial criteria
- Age ≥ 4 years
- Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD)
- Crenessity is used as adjunctive treatment to glucocorticoid replacement
- Member meets one of the following: supraphysiological glucocorticoid dosing OR high levels of androstenedione or 17-hydroxyprogesterone
Reauthorization criteria
- Member has experienced a reduction in daily glucocorticoid dose OR has experienced improvement or stabilization in androgen levels
Approval duration
Initial: up to 6 months; Reauthorization: up to 12 months